miR-140-5 p通过调控Wnt1通路对非小细胞肺癌迁移与侵袭能力的影响

目的:探究miR-140-5p通过Wnt1通路对非小细胞肺癌(NSCLC)细胞迁移、侵袭的影响,为临床对NSCLC的治疗提供理论依据.方法:临床收集人NSCLC组织及癌旁组织20组,RT-PCR检测miR-140-5p与Wnt1基因的表达水平,Spearman相关分析法比较miR-140-5p与Wnt1基因表达水平的相...     

miR-708-5p通过靶向URGCP抑制非小细胞肺癌A549细胞侵袭、转移的研究

目的 探讨miR-708-5p对非小细胞肺癌A549细胞的增殖、迁移和侵袭的影响及其与上调基因-4(upregulated gene-4/upregulator of cell proliferation,URG4/URGCP)的靶向关系.方法 选取非小细胞肺癌细胞株A549,正常肺成纤维细胞HLF-1为研究对象,根据...     

miR-409-3p靶向癌基因ELF2抑制非小细胞肺癌细胞系A549增殖

目的观察miR-409-3p对非小细胞肺癌细胞系A549增殖的影响及其机制。方法对照组为常规条件下培养的转染阳性对照核苷酸的A549细胞寡核苷酸组。实验组在对照组的基础上采用化学合成miR-409-3p模拟物,脂质体转染构建miR-409-3p高表达A549细胞;经q PCR检测,观察2组48 h后miR-409-3p的表达; MTT法检测细胞增殖;流式细胞计量术检测细胞凋亡和周期的差异。结果 miR-409-3p模拟物转染后,A549细胞中miR-409-3p表达水平显著升高(P0. 05);细胞总凋亡比例为22. 66%±4. 61%,显著高于对照组的7. 78%±1. 95%(P0. 05); G0/G1期为40. 21%±5. 37%,显著低于对照组细胞56. 09%±5. 22%(P0. 05);双荧光报告系统表明癌基因ELF2是miR-409-3p的靶基因,过表达miR-409-3p模拟物后,内源性ELF2蛋白表达水平显著下降(P0. 05)。结论 miR-409-3p可能通过调控ELF2的转录水平抑制非小细胞肺癌细胞A549增殖并促进其凋亡。     

miR-141-3p通过靶向PDCD1抑制人胃癌细胞系AGS的迁移与侵袭

目的 探讨miR-141-3p对胃癌(GC)细胞迁移与侵袭的影响,并揭示其潜在的分子机制.方法 用RT-qPCR分别检测临床组织样本、正常胃黏膜上皮细胞系GES-1和胃癌细胞系AGS中miR-141-3p的表达.在AGS细胞中转染miR-141-3p mimic后,用Transwell小室法检测细胞的迁移和侵袭;荧光素...     

miR-95-5p介导SATB1-Wnt信号通路抑制非小细胞肺癌细胞活力和侵袭能力

目的:研究miR-95-5p对非小细胞肺癌(NSCLC)细胞增殖和侵袭的作用及机制.方法:RT-qPCR检测NSCLC组织和细胞中miR-95-5p与SATB1 mRNA的表达,利用Lipofectamine2000将miR-NC、miR-95-5p mimic、pc-NC、pc-SATB1质粒分别或联合转染至H165...     

LncRNA XIST通过调控miR-140-3p/PD-L1轴促进弥漫大B细胞淋巴瘤细胞的增殖与迁移

目的 探讨LncRNA X失活特异性转录本（XIST）通过miR-140-3p/程序性死亡配体-1(PD-L1)轴对弥漫大B细胞淋巴瘤（DLBCL）细胞增殖、迁移的影响。方法 以2015年至2017年期间我科室收治的40例DLBCL患者的淋巴结活检组织标本,以及人DLBCL细胞系OCI-LY19、SU-DHL-4、U2932为研究对象,qRT-PCR检测XIST表达,分析XIST表达与DLBCL患者临床病理特征的关系;利用LipofectamineTM2000转染试剂对U2932细胞进行转染,分组为：空白组、miR-NC组、miR-140-3p mimics组、OE-NC组、OE-XIST组、OE-PD-L1组、OE-XIST+miR-NC组、OE-XIST+miR-140-3p mimics组、OE-XIST+si-NC组、OEXIST+si-PD-L1组,qRT-PCR检测各组细胞中miR-140-3p及XIST表达水平;MTT法检测各组细胞增殖情况;Transwell实验检测各组细胞迁移情况;双荧光素酶报告基因检测实验分别验证XIST与miR-140-3p、miR-140-3p与...     

LncRNA TUG1调控miR-142-5p/PD-L1轴促进非小细胞肺癌细胞增殖、迁移与侵袭能力

目的 探讨长链非编码RNA(long non-coding RNA, LncRNA)牛磺酸上调基因1(taurine up-regulated gene 1, TUG1)对非小细胞肺癌(non-small cell lung cancer, NSCLC)细胞生物学行为的影响及分子机制。方法 采用qRT-PCR、Western blot分别检测组织(NSCLC癌组织、癌旁组织)和细胞(人正常气管上皮细胞HBE及NSCLC细胞A549、H2009、H1975)中TUG1、miR-142-5p及PD-L1的表达。将pcDNA-TUG1、si-TUG1、miR-142-5p mimics、si-TUG1+anti-miR-142-5p分别转染于A549,qRT-PCR、Western blot分别检测细胞中TUG1、miR-142-5p及PD-L1表达;CCK-8检测细胞增殖;Transwell检测细胞迁移、侵袭;双荧光素酶基因实验分别检测TUG1和miR-142-5p、miR-142-5p和PD-L1的关系;RNA免疫共沉淀检测miR-142-5p与TUG1的相互作用。结果 NSCLC组织中...     

miR-556-3p通过靶基因SASH1调控子宫内膜癌细胞的活力、迁移和侵袭

目的:研究微小RNA-556-3p(miR-556-3p)是否通过靶向SASH1基因调控子宫内膜癌细胞的活力、迁移和侵袭。方法:采用RT-qPCR和Western blot检测miR-556-3p和SASH1的mRNA和蛋白在子宫内膜癌组织中的表达。向子宫内膜癌Ishikawa细胞转染anti-miR-556-3p或pcDNA-SASH1,采用MTT法检测细胞活力,Transwell小室法检测细胞迁移和侵袭能力,Western blot检测细胞周期蛋白D1(cyclin D1)、p21、基质金属蛋白酶2(MMP-2)和MMP-9蛋白的表达。StarBase预测和双萤光素酶报告实验分析miR-556-3p和SASH1的靶向关系。将anti-miR-556-3p和si-SASH1共转染Ishikawa细胞,采用上述方法检测其对细胞活力、迁移和侵袭能力的影响。结果:与癌旁组织比较,子宫内膜癌组织中miR-556-3p的表达量显著增加,SASH1的mRNA和蛋白表达量显著减少(P<0.05)。抑制miR-556-3p表达或使SASH1过表达显著降低Ishikawa细胞活力、迁移细胞数、侵...     

p21活化激酶6削弱非小细胞肺癌A549细胞侵袭及迁移能力的分子机制

 目的：探讨调控p21活化激酶6(PAK6)的微小RNA（miRNA）与非小细胞肺癌侵袭及迁移的关系,并了解PAK6下游分子信号机制。方法：通过生物信息学数据库预测靶向PAK6的miRNA,转染miRNA模拟物及抑制剂,Western blotting及实时定量荧光PCR（real-time PCR）检测A549细胞中PAK6的表达量,萤光素报告酶实验检测预测miRNA对PAK6的调控,并行体外迁移及侵袭实验,检测转染miRNA对PC-3细胞迁移及侵袭能力的影响。转染目标miRNA及siPAK6,Western blotting检测A549细胞基质金属蛋白酶9（MMP-9）表达量。结果：生物信息学预测miR-23a可能是调控PAK6的靶向miRNA。Western blotting检测转染miR-23a组PAK6表达量下降69％,而转染miR-23a抑制剂组PAK6表达量上升52％,差异均有统计学意义。萤光素报告酶实验结果显示,转染miR-23a后野生型PAK6组萤光素酶活性下降52％,而突变组差异无统计学意义（P＞0.05）。Real-time PCR检测3组PAK6 mRNA的表达差异无统计学意义（P＞0.05）。体外迁移及侵袭实验示,转染miR-23a组迁移细胞数减少73％,侵袭的细胞数减少59％。Western blotting检测发现,转染siPAK6组MMP-9的表达下降85％（P＜0.01）,转染miR-23a组MMP-9的表达下降76％（P＜0.01）。结论：miR-23a通过PAK6-MMP-9信号途径引起非小细胞肺癌细胞迁移及侵袭能力的下降。     

miR-454-3p靶向BPTF表达调控肺癌细胞A549增殖、迁移和侵袭

目的探讨miR-454-3p对肺癌细胞增殖、迁移和侵袭的影响及分子机制。方法采用RT-PCR技术检测miR-454-3p在肺癌组织以及肺癌细胞株中的表达,以表达量最低的肺癌细胞A549为后续分析对象,将miR-454-3p mimic转入A549细胞,RT-PCR验证miR-454-3p的过表达效率;采用CCK-8、迁移、侵袭等实验,观察转染组与对照组肺癌细胞的增殖、迁移和侵袭情况;生物信息学预测BPTF是miR-454-3p的靶标,构建BPTF 3′UTR荧光素酶载体,通过双荧光素酶报告基因验证miR-454-3p和BPTF的靶向关系;应用Western blot法检测BPTF的表达及迁移、侵袭相关蛋白的变化。结果RT-PCR实验表明miR-454-3p在肺癌组织和细胞中表达下调,且在A549细胞中表达最低(P<0.05)。与对照组相比,过表达miR-454-3p的肺癌细胞A549增殖能力明显降低,迁移和侵袭能力均受到抑制(P<0.05)。生物信息学软件分析BPTF为miR-454-3p的潜在靶基因,过表达miR-454-3p后BPTF的表达水平明显受到抑制。同时,迁移相关蛋白MMP-2和MMP-9表达明显下调,E-cadhern表达明显上调,而E-cadherin的负性调控N-cadherin表达下降。结论miR-454-3p可能通过靶向下调BPTF的表达,抑制肺癌细胞的增殖、迁移和侵袭能力,为肺癌的靶向治疗提供潜在靶标。     

p21活化激酶6对人非小细胞肺癌A549细胞侵袭及迁移能力的影响

 目的：探讨p21活化激酶6（PAK6）对非小细胞肺癌侵袭及迁移能力的影响及机制研究。方法：实时荧光定量PCR检测人非小细胞肺癌A548细胞、人支气管上皮细胞、非小细胞肺癌组织及癌旁组织中PAK6 mRNA的表达。A549细胞分别转染siRNA-PAK6（siPAK6组）和阴性对照（对照组）,实时荧光定量PCR技术检测PAK6 mRNA,Western blotting检测PAK6表达量;并行体外迁移及侵袭实验,检测转染siRNA-PAK6对A549细胞侵袭及迁移能力的影响;共聚焦显微镜观察细胞骨架的改变。结果：A549细胞中PAK6 mRNA的表达量明显高于人支气管上皮细胞中PAK6 mRNA的表达量（3.50±1.16 vs 1.12±0.42,P<0.05）,非小细胞肺癌组织中PAK6 mRNA的表达量明显高于癌旁组织中PAK6 mRNA的表达量（5.13±1.33  vs 1.08±0.37,P<0.05）。A549细胞转染siPAK6后,PAK6蛋白表达量下降72%（P<0.05）,PAK6 mRNA水平明显下降（3.72±0.75 vs  0.69±0.21,P<0.05）。A549细胞转染siPAK6组侵袭及迁移出的细胞数量明显少于对照组(P<0.05)。siPAK6组A549细胞骨架应力纤维减少明显,肌动蛋白皱缩。结论：PAK6通过细胞骨架的重构影响非小细胞肺癌的侵袭及迁移能力。     

miR-197-3p调控DMBT1抑制甲状腺癌细胞系增殖、迁移和侵袭

目的探讨miR-197-3p是否通过靶向调控恶性脑瘤缺失1基因(DMBT1)影响甲状腺癌细胞增殖、迁移和侵袭。方法RT-qPCR检测健康人甲状腺细胞Nthy-ori 3-1和甲状腺癌细胞SW579、CGTHW-1中miR-197-3p表达;MTT法检测SW579细胞增殖;Transwell小室法检测SW579细胞迁移和侵袭;双荧光素酶报告基因实验验证miR-197-3p是否靶向DMBT1;Western blot检测细胞DMBT1、cyclinD1、p21、MMP-2和E-cadherin蛋白表达。结果与Nthy-ori 3-1细胞比较,SW579和CGTHW-1细胞中miR-197-3p相对表达量升高(P<0.05);抑制miR-197-3p表达后,SW579细胞的增殖、迁移和侵袭能力明显受到抑制,细胞中cyclinD1蛋白和MMP-2蛋白表达降低而p21蛋白和E-cadherin蛋白表达升高;SW579细胞中miR-197-3p靶向负调控DMBT1的表达;过表达DMBT1明显抑制SW579细胞增殖、迁移和侵袭,而抑制DMBT1则能逆转miR-197-3p对SW579细胞增殖、迁移和侵袭的影响。结论miR-197-3p通过靶向调控DMBT1的表达,抑制甲状腺癌细胞增殖、迁移和侵袭。     

Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer

Lung cancer remains the most common cancer and the leading cause of cancer death worldwide. Despite effective chemotherapy and molecular-based therapies, the median and overall survival remains poor. Immune checkpoint inhibitors have changed the treatment landscape for patients with non-small cell lung cancer (NSCLC) by inhibiting negative T cell regulators, including programmed death 1 (PD-1, CD279) and programmed death ligand 1 (PD-L1, also known as B-H1, CD274) inhibitors. Nonetheless, most patients do not respond to these inhibitors. Recently, PD-L1 expression has been demonstrated to influence the anti-tumor efficacy of immune checkpoint inhibitors. However, the mechanisms of PD-L1 regulation are not clearly understood. This review thus aims to summarize the current knowledge and recent developments in the regulatory mechanisms of PD-L1 expression levels and attempts to clarify its latent function in anti-tumor activity, with the goal of guiding better designs for future NSCLC immunotherapies.     

miR-338-3p inhibits the proliferation and migration of gastric cancer cells by targeting ADAM17

Background: MicroRNAs (miRNA) have been documented playing a critical role in cancer progression. Although miR-338-3p has been implicated in several cancers, its role in gastric cancer is still unknown. The aim of our study was to investigate the role of miR-338-3p in gastric cancer progression. Methods: Expression levels of miR-338-3p in gastric cancer cell lines and tissues were determined by quantitative real-time PCR (qRT-PCR). The effect of miR-338-3p on proliferation was evaluated by MTT assay, cell migration and invasion were evaluated by transwell migration and invasion assays. Furthermore, luciferase reporter assay was conducted to confirm the target gene of miR-338-3p, and the results were validated in gastric cancer cells. Results: In the present study, we found that miR-338-3p was down-regulated in both gastric cancer cell lines and tissues. Enforced expression of miR-338-3p inhibited proliferation, migration and invasion of gastric cancer cells in vitro. Moreover, we identified A disintegrin and metalloproteinase 17 (ADAM17) gene as potential target of miR-338-3p. Importantly, ADAM17 rescued the miR-338-3p mediated inhibition of cell proliferation, migration and invasion. Conclusions: Our study suggested that miR-338-3p is significantly decreased in gastric cancer, and inhibits cell proliferation, migration and invasion partially via the downregulation of ADAM17. Thus, miR-338-3p may represent a potential therapeutic target for gastric cancer intervention.     

miR-128-3p过表达靶向MAPK1抑制膀胱癌5637细胞株的侵袭，迁移和上皮间质转化

目的　研究miR-128-3p过表达对膀胱癌5637细胞株的侵袭,迁移和上皮间质转化影响。 方法　基因预测软件TargetScan筛选出miR-128-3p的靶基因,荧光素酶报告实验验证;RT-PCR检测miR-128-3p和MAPK1的表达,Transwell检测细胞侵袭情况,划痕实验检测细胞迁移能力,Western blot检测E-cadherin、N-cadherin、ERK1/2、c-Myc和c-fos的表达,免疫荧光检测Vimentin的表达;裸鼠皮下注射建立移植瘤模型,30 d后检测瘤重量,绘制存活曲线,检测移植瘤中Vimentin、miR-128-3p、MAPK1、ERK1/2、c-Myc和c-fos的量。 结果　miR-128-3p靶向抑制MAPK1表达;miR-128-3p过表达后,侵袭细胞数目、伤口愈合率降低,E-cadherin表达上调,N-cadherin表达下调,Vimentin阳性率减少,p-ERK1/2、c-Myc和c-fos表达下调。经miR-128-3p干预,裸鼠体内移植瘤重量减轻,存活率增加,miR-128-3p表达上调,MAPK1的表达下调,Vimentin阳性率减少,p-ERK1/2、c-Myc和c-fos表达下调。 结论　过表达miR-128-3p通过靶向抑制MAPK1表达来抑制膀胱癌细胞5637的侵袭能力、迁移能力、上皮-间充质转化和ERK1/2、c-Myc和c-fos通路。     

miR-128-3p过表达靶向MAPK1抑制膀胱癌5637细胞株的侵袭，迁移和上皮间质转化

目的　研究miR-128-3p过表达对膀胱癌5637细胞株的侵袭,迁移和上皮间质转化影响。 方法　基因预测软件TargetScan筛选出miR-128-3p的靶基因,荧光素酶报告实验验证;RT-PCR检测miR-128-3p和MAPK1的表达,Transwell检测细胞侵袭情况,划痕实验检测细胞迁移能力,Western blot检测E-cadherin、N-cadherin、ERK1/2、c-Myc和c-fos的表达,免疫荧光检测Vimentin的表达;裸鼠皮下注射建立移植瘤模型,30 d后检测瘤重量,绘制存活曲线,检测移植瘤中Vimentin、miR-128-3p、MAPK1、ERK1/2、c-Myc和c-fos的量。 结果　miR-128-3p靶向抑制MAPK1表达;miR-128-3p过表达后,侵袭细胞数目、伤口愈合率降低,E-cadherin表达上调,N-cadherin表达下调,Vimentin阳性率减少,p-ERK1/2、c-Myc和c-fos表达下调。经miR-128-3p干预,裸鼠体内移植瘤重量减轻,存活率增加,miR-128-3p表达上调,MAPK1的表达下调,Vimentin阳性率减少,p-ERK1/2、c-Myc和c-fos表达下调。 结论　过表达miR-128-3p通过靶向抑制MAPK1表达来抑制膀胱癌细胞5637的侵袭能力、迁移能力、上皮-间充质转化和ERK1/2、c-Myc和c-fos通路。     

miR-593-5p inhibit cell proliferation by targeting PLK1 in non small cell lung cancer cells

Worldwide, lung cancer has the highest rates of mortality and morbidity, with the majority of its pathology attributable to non-small cell lung cancer (NSCLC). MicroRNAs are pivotal in the occurrence and development of cancer. However, the role of miRNA-593-5p in the progression of NSCLC is not clear. In this study, we investigate, in vitro, whether miRNA-593-5p inhibits NSCLC cell proliferation. To clarify its specific mechanism of inhibition, we used bioinformatics to predict its target genes and identified PLK1. Luciferase reporter assay confirmed the binding of miR-593-5p to the PLK1 3′-UTR in a sequence-specific manner in NSCLC cells. Additionally, we also found through Western blot and quantitative RT-PCR that miR-593-5p down-regulates the expression of PLK1 protein. Finally, PLK1 overexpression was shown to disinhibit NSCLC cell proliferation. Taken together, this evidence suggests that miR-593-5p inhibits NSCLC cell proliferation by inhibiting PLK1 expression.     

miR-485-5p靶向作用于SOX5抑制肝癌细胞Hep3B的活力及侵袭和迁移能力

目的:研究微小RNA-485-5p(miR-485-5p)对肝癌细胞的活力及迁移和侵袭能力的影响及其潜在机制。方法:以正常肝细胞THLE-3为对照,采用RT-qPCR检测肝癌细胞中性别决定区Y框蛋白5(SOX5)mRNA和miR-485-5p的表达,Western blot检测SOX5、增殖细胞核抗原(PCNA)、Ki67、细胞周期蛋白D1(cyclin D1)及基质金属蛋白酶2(MMP-2)的表达水平,MTT法检测Hep3B细胞的活力,Transwell实验检测细胞的迁移和侵袭能力,双萤光素酶报告基因系统验证细胞中miR-485-5p与SOX5的调控关系。结果:与对照组相比,在肝癌细胞Hep3B、Huh7和HCCLM3中miR-485-5p的表达水平显著降低(P<0.05),SOX5的mRNA和蛋白表达水平均显著升高(P<0.05);过表达miR-485-5p可抑制Hep3B细胞的活力及迁移和侵袭能力(P<0.05);miR-485-5p靶向调控SOX5的表达,敲减SOX5的表达也可抑制Hep3B细胞的活力及迁移和侵袭能力;过表达SOX5可部分逆转过表达miR-48...